MCID: ACT135
MIFTS: 57

Acute Graft Versus Host Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Graft Versus Host Disease

MalaCards integrated aliases for Acute Graft Versus Host Disease:

Name: Acute Graft Versus Host Disease 53 59
Acute Graft-Versus-Host Disease 55
Acute Gvh Disease 73
Acute Gvhd 53

Classifications:

Orphanet: 59  
Rare immunological diseases


External Ids:

Orphanet 59 ORPHA99920
ICD10 via Orphanet 34 T86.0
UMLS via Orphanet 74 C0856825
UMLS 73 C0856825

Summaries for Acute Graft Versus Host Disease

MalaCards based summary : Acute Graft Versus Host Disease, also known as acute graft-versus-host disease, is related to graft-versus-host disease and hematopoietic stem cell transplantation. An important gene associated with Acute Graft Versus Host Disease is ARHGAP45 (Rho GTPase Activating Protein 45), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Basiliximab and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Acute Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Acute Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 303)
# Related Disease Score Top Affiliating Genes
1 graft-versus-host disease 31.3 ARHGAP45 FASLG GZMB IFNG IL10 IL2
2 hematopoietic stem cell transplantation 31.2 ARHGAP45 IFNG IL10 IL2 TNF
3 chronic graft versus host disease 30.3 IFNG IL10 IL2RA TNF
4 mouth disease 30.1 IFNG IL10 TNF
5 aspergillosis 30.1 IFNG IL10 IL4 TNF
6 bronchiolitis 29.9 IFNG IL10 IL4 TNF
7 erythema multiforme 29.8 FASLG GZMB IFNG IL2 TNF
8 lymphopenia 29.8 FASLG IFNG IL2 IL2RA
9 bronchiolitis obliterans 29.7 GZMB IFNG IL10 TNF
10 lichen planus 29.7 GZMB IFNG IL4 TNF
11 severe cutaneous adverse reaction 29.6 FASLG GZMB TNF
12 aplastic anemia 29.6 FASLG IFNG IL2 IL4 TNF
13 colitis 29.5 IFNG IL10 IL2 IL4 NOD2 TNF
14 inflammatory bowel disease 29.3 IFNG IL10 IL18 IL2 IL4 NOD2
15 leukemia 10.6
16 tuberculoid leprosy 10.3 IFNG IL10
17 fungal meningitis 10.3 IFNG IL10
18 sporotrichosis 10.3 IFNG IL10
19 pericardial tuberculosis 10.3 IFNG IL10
20 retinitis pigmentosa 44 10.3 IL10 IL2
21 variola major 10.3 IFNG IL2
22 berylliosis 10.3 IFNG IL2
23 cow milk allergy 10.3 IL10 TNF
24 choroiditis 10.3 IL10 TNF
25 trachoma 10.3 IL10 TNF
26 trichuriasis 10.3 IL10 TNF
27 transient hypogammaglobulinemia 10.3 IL10 TNF
28 mucocutaneous leishmaniasis 10.3 IL10 TNF
29 trichosporonosis 10.3 IFNG TNF
30 idiopathic achalasia 10.3 IL10 TNF
31 fixed drug eruption 10.3 IFNG IL2
32 microscopic polyangiitis 10.3 IL10 TNF
33 multifocal choroiditis 10.3 IL10 TNF
34 cardiac sarcoidosis 10.3 IFNG TNF
35 miliary tuberculosis 10.3 IFNG TNF
36 microscopic colitis 10.3 IL2 TNF
37 staphylococcal toxic shock syndrome 10.3 IFNG TNF
38 chronic beryllium disease 10.3 IFNG TNF
39 farmer's lung 10.3 IL2 TNF
40 retinitis pigmentosa 22 10.3 IL10 IL4
41 apple allergy 10.3 IL10 IL4
42 beta-lactam allergy 10.3 IL10 IL4
43 eosinophilic meningitis 10.3 IL10 IL4
44 streptococcal toxic-shock syndrome 10.3 IL2 TNF
45 b-cell growth factor 10.3 IFNG IL4
46 cervicitis 10.3 IL2 IL2RA
47 crustacean allergy 10.3 IFNG IL4
48 spondylocarpotarsal synostosis syndrome 10.3
49 autoimmune vasculitis 10.3 IL2 IL4
50 angiostrongyliasis 10.3 IL2 IL4

Graphical network of the top 20 diseases related to Acute Graft Versus Host Disease:



Diseases related to Acute Graft Versus Host Disease

Symptoms & Phenotypes for Acute Graft Versus Host Disease

GenomeRNAi Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 GZMB IL10 IL18 IL2 IL2RA NOD2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 GZMB IL10 IL18 IL2 IL2RA NOD2

MGI Mouse Phenotypes related to Acute Graft Versus Host Disease:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 FASLG IFNG IL10 IL18 IL2 IL4
2 digestive/alimentary MP:0005381 10.21 FASLG IFNG IL10 IL18 IL2 IL2RA
3 hematopoietic system MP:0005397 10.2 FASLG IFNG IL10 IL18 IL2 IL2RA
4 growth/size/body region MP:0005378 10.18 IFNG IL10 IL18 IL2 IL2RA IL4
5 homeostasis/metabolism MP:0005376 10.17 FASLG IFNG IL10 IL18 IL2 IL2RA
6 immune system MP:0005387 10.14 FASLG IFNG IL10 IL18 IL2 IL2RA
7 endocrine/exocrine gland MP:0005379 10.04 FASLG IFNG IL10 IL2 IL2RA IL4
8 mortality/aging MP:0010768 10 FASLG IFNG IL10 IL18 IL2 IL2RA
9 integument MP:0010771 9.91 FASLG IFNG IL10 IL18 IL4 TNF
10 liver/biliary system MP:0005370 9.87 FASLG IFNG IL10 IL2 IL4 TNF
11 no phenotypic analysis MP:0003012 9.63 IFNG IL10 IL2 IL4 MYH9 TNF
12 respiratory system MP:0005388 9.56 FASLG IFNG IL10 IL2 IL2RA IL4
13 vision/eye MP:0005391 9.28 FASLG IFNG IL10 IL18 IL2 IL2RA

Drugs & Therapeutics for Acute Graft Versus Host Disease

Drugs for Acute Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 152923-56-3, 179045-86-4
2
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
3
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
4
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
6
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
8
Lomustine Approved, Investigational Phase 4,Not Applicable 13010-47-4 3950
9
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147-94-4 6253
10
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
11
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 104987-11-3 445643 439492
12
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
13
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
14
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
15
Foscarnet Approved Phase 4,Not Applicable 63585-09-1, 4428-95-9 3415
16
Ganciclovir Approved, Investigational Phase 4,Not Applicable 82410-32-0 3454
17
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
19
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
20 Semustine Experimental, Investigational Phase 4,Not Applicable 13909-09-6
21
Treosulfan Investigational Phase 4,Phase 2,Phase 3,Phase 1 299-75-2 9296
22
Phosphonoacetic Acid Experimental Phase 4,Not Applicable 4408-78-0 546
23 Folate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
30 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Thymoglobulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 875)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
3 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
4 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
5 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Completed NCT02412423 Phase 4 post-transplantation cyclophosphamide
6 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
7 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
8 PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil
9 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
10 ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
11 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
12 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
13 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
14 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
15 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
16 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
17 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
18 Extracorporeal Photopheresis for Acute Graft Versus Host Disease Unknown status NCT00179855 Phase 2, Phase 3
19 MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
20 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3 Cyclophosphamide
21 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
22 Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
23 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
24 MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment Unknown status NCT02240992 Phase 2, Phase 3
25 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Unknown status NCT01295710 Phase 3
26 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
27 TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID Unknown status NCT02327351 Phase 2, Phase 3
28 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
29 Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
30 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
31 Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3 Prochymal
32 Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease Completed NCT00366145 Phase 3
33 Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) Completed NCT00655343 Phase 3 ATG-Fresenius S
34 Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease Completed NCT00053976 Phase 3 methylprednisolone;Placebo
35 A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT02336230 Phase 3 remestemcel-L
36 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
37 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
38 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed NCT00130754 Phase 3 Thymoglobuline
39 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
40 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
41 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate
42 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
43 Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Completed NCT00002456 Phase 3 cyclosporine;methotrexate
44 Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate
45 Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies Completed NCT00275678 Phase 3
46 Nonmyeloablative Stem Cell Transplant in Elderly Completed NCT00382759 Phase 2, Phase 3
47 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
48 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
49 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
50 Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3 StemEx®

Search NIH Clinical Center for Acute Graft Versus Host Disease

Genetic Tests for Acute Graft Versus Host Disease

Anatomical Context for Acute Graft Versus Host Disease

MalaCards organs/tissues related to Acute Graft Versus Host Disease:

41
T Cells, Bone, Bone Marrow, Myeloid, Skin, Liver, Nk Cells

Publications for Acute Graft Versus Host Disease

Articles related to Acute Graft Versus Host Disease:

(show top 50) (show all 1076)
# Title Authors Year
1
Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. ( 30344086 )
2019
2
Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. ( 29380038 )
2018
3
Change of apheresis device decreased the incidence of severe acute graft-versus-host disease among patients after allogeneic stem cell transplantation with sibling donors. ( 29536557 )
2018
4
TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells. ( 29960041 )
2018
5
The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay. ( 29643984 )
2018
6
Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. ( 29345306 )
2018
7
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease. ( 29351985 )
2018
8
Photopheresis of a less than 10-kg child with acute graft versus host disease accompanied with hyperbilirubinemia: A case report. ( 29778715 )
2018
9
The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease. ( 29763906 )
2018
10
MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. ( 29720426 )
2018
11
Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. ( 29403494 )
2018
12
Plasma vascular non-inflammatory molecule 3 is associated with gastrointestinal acute graft-versus-host disease in mice. ( 29311761 )
2018
13
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. ( 29755674 )
2018
14
Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience. ( 29707788 )
2018
15
Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? ( 29446444 )
2018
16
18F-3'-deoxy-3'-fluorothymidine (FLT) PET imaging for the prediction of acute graft-versus-host disease in mouse hematopoietic stem cell transplant models. ( 29981461 )
2018
17
Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival. ( 29391524 )
2018
18
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. ( 29684567 )
2018
19
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). ( 29379171 )
2018
20
Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease. ( 29371686 )
2018
21
Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. ( 29795434 )
2018
22
Acute Graft-versus-Host Disease. ( 29419277 )
2018
23
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease <i>via</i> the Treg/Th17 Balance in Allo-HSCT Recipients. ( 29740427 )
2018
24
Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. ( 29795429 )
2018
25
Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients. ( 29667720 )
2018
26
Regulatory I^I' T cells induced by G-CSF participate in acute graft-versus-host disease regulation in G-CSF-mobilized allogeneic peripheral blood stem cell transplantation. ( 29801459 )
2018
27
Association analysis between SUFU polymorphism rs17114808 and acute graft versus host disease after hematopoietic stem cell transplantation. ( 29330404 )
2018
28
Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients. ( 29427741 )
2018
29
Acute Graft-versus-Host Disease. ( 29414273 )
2018
30
Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. ( 29346409 )
2018
31
CXCR3 blockade combined with cyclosporine A alleviates acute graft-versus-host disease by inhibiting alloreactive donor T cell responses in a murine model. ( 29288898 )
2018
32
MicroRNA in T-Cell Development and T-Cell Mediated Acute Graft-Versus-Host Disease. ( 29867969 )
2018
33
Extracorporeal photopheresis is a valuable treatment option in steroid-refractory or steroid-dependent acute graft versus host disease-experience with three different approaches. ( 29907805 )
2018
34
I+<sub>1</sub>-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease. ( 29437593 )
2018
35
Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. ( 29800615 )
2018
36
Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. ( 29670210 )
2018
37
Acute graft-versus-host disease following lung transplantation in a patient with a novel<i>TERT</i>mutation. ( 29382801 )
2018
38
Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples. ( 30004111 )
2018
39
Photoconversion of Alloreactive T Cells in Murine Peyer's Patches During Acute Graft-Versus-Host Disease: Tracking the Homing Route of Highly Proliferative Cells In Vivo. ( 30013554 )
2018
40
PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation. ( 30019128 )
2018
41
Low mean post-transplantation tacrolimus levels in weeks 2-3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. ( 30038351 )
2018
42
Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease. ( 30042760 )
2018
43
Human Herpesvirus-6 Reactivation and Acute Graft-versus-Host Disease. ( 30048732 )
2018
44
Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. ( 30076185 )
2018
45
Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model. ( 30084111 )
2018
46
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. ( 30087106 )
2018
47
High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. ( 30108323 )
2018
48
Retrospective analysis on transient recurrence of steroid-sensitive acute graft-versus-host disease. ( 30108328 )
2018
49
Recipient-derived IL-22 alleviates murine acute graft-versus-host disease in association with reduced activation of antigen presenting cells. ( 30114627 )
2018
50
The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation ( 30119155 )
2018

Variations for Acute Graft Versus Host Disease

Expression for Acute Graft Versus Host Disease

Search GEO for disease gene expression data for Acute Graft Versus Host Disease.

Pathways for Acute Graft Versus Host Disease

Pathways related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 ARHGAP45 FASLG IFNG IL10 IL18 IL2
2
Show member pathways
13.82 FASLG IL10 IL18 IL2 IL2RA IL4
3
Show member pathways
13.67 FASLG IFNG IL10 IL18 IL2 IL2RA
4
Show member pathways
13.49 IFNG IL10 IL18 IL2 IL2RA IL4
5
Show member pathways
13.41 FASLG IL10 IL18 IL2 IL2RA IL4
6
Show member pathways
13.35 FASLG IFNG IL10 IL18 IL2 IL2RA
7
Show member pathways
13.29 FASLG IL10 IL18 IL2 IL2RA IL4
8
Show member pathways
13.05 FASLG IFNG IL10 IL18 IL2 NOD2
9
Show member pathways
12.96 FASLG IL2 IL2RA IL4 TNF
10
Show member pathways
12.87 FASLG GZMB IFNG IL10 IL18 IL2
11 12.83 FASLG IFNG IL2 IL2RA IL4
12
Show member pathways
12.82 FASLG IFNG IL18 IL2 IL2RA IL4
13
Show member pathways
12.67 IFNG IL10 IL18 IL2 IL2RA IL4
14
Show member pathways
12.62 IFNG IL10 IL18 IL2 TNF
15
Show member pathways
12.58 FASLG GZMB IFNG IL2 IL4 TNF
16
Show member pathways
12.57 IFNG IL10 IL18 IL2 IL2RA IL4
17
Show member pathways
12.48 IFNG IL10 IL2 IL4 TNF
18
Show member pathways
12.44 IFNG IL10 IL2 IL2RA IL4
19
Show member pathways
12.34 IFNG IL2 IL4 TNF
20 12.32 FASLG GZMB IFNG IL10 IL2 IL2RA
21 12.31 IFNG IL10 IL18 NOD2 TNF
22
Show member pathways
12.3 IFNG IL10 IL18 IL2 IL2RA IL4
23
Show member pathways
12.28 IFNG IL10 IL4 TNF
24
Show member pathways
12.21 FASLG IFNG IL4 TNF
25
Show member pathways
12.14 IFNG IL10 IL18 IL2 IL2RA IL4
26
Show member pathways
12.14 IFNG IL10 IL18 IL2 TNF
27 12.07 FASLG IL10 IL18 IL4 TNF
28 12.07 IFNG IL10 IL2 IL2RA IL4 TNF
29 12.06 IFNG IL2 IL4 TNF
30
Show member pathways
12.03 IFNG IL2 IL2RA
31
Show member pathways
12 IFNG IL4 TNF
32 11.93 IFNG IL10 IL2 IL2RA
33 11.88 IL2RA IL4 TNF
34 11.88 IFNG IL10 TNF
35 11.85 IFNG IL18 TNF
36
Show member pathways
11.85 FASLG GZMB IFNG IL18 IL2 IL2RA
37 11.83 IFNG IL18 MYH9
38 11.83 IFNG IL10 IL2 TNF
39 11.8 IFNG IL2 IL4
40
Show member pathways
11.79 FASLG IL2 IL2RA IL4
41
Show member pathways
11.76 FASLG IFNG IL2 IL2RA IL4 TNF
42 11.7 IFNG IL10 IL18 IL2 IL4 TNF
43
Show member pathways
11.68 IFNG IL2 TNF
44 11.65 FASLG IFNG IL2 TNF
45 11.63 IL10 IL18 IL4 TNF
46 11.62 IFNG IL10 IL18 TNF
47 11.56 IFNG IL2 TNF
48 11.56 IFNG IL18 TNF
49 11.52 FASLG IFNG TNF
50 11.46 IFNG IL10 IL2 IL2RA IL4 TNFRSF4

GO Terms for Acute Graft Versus Host Disease

Cellular components related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 FASLG IFNG IL10 IL18 IL2 IL4
2 external side of plasma membrane GO:0009897 9.56 FASLG IL2RA TNF TNFRSF4
3 cell surface GO:0009986 9.35 FASLG IL2RA NOD2 TNF TNFRSF4
4 extracellular region GO:0005576 9.23 ARHGAP45 FASLG IFNG IL10 IL18 IL2

Biological processes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 IFNG IL18 IL4 TNF
2 inflammatory response GO:0006954 9.98 IL10 IL18 TNF TNFRSF4
3 MAPK cascade GO:0000165 9.89 IL18 IL2 IL2RA TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 IL18 NOD2 TNF
5 negative regulation of inflammatory response GO:0050728 9.84 IL10 IL2 IL2RA
6 positive regulation of inflammatory response GO:0050729 9.82 IL18 IL2 TNF
7 cellular response to organic cyclic compound GO:0071407 9.81 IL18 NOD2 TNF
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.81 FASLG TNF TNFRSF4
9 positive regulation of T cell proliferation GO:0042102 9.76 IL2 IL2RA IL4
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.75 IL18 NOD2 TNF
11 extrinsic apoptotic signaling pathway GO:0097191 9.73 FASLG IFNG TNF
12 positive regulation of interferon-gamma production GO:0032729 9.72 IL18 IL2 TNF
13 regulation of signaling receptor activity GO:0010469 9.7 FASLG IFNG IL10 IL18 IL2 IL4
14 protein import into nucleus, translocation GO:0000060 9.69 IFNG TNF
15 natural killer cell mediated cytotoxicity GO:0042267 9.69 GZMB IL18
16 positive regulation of osteoclast differentiation GO:0045672 9.68 IFNG TNF
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 IFNG TNF
18 negative regulation of growth of symbiont in host GO:0044130 9.67 IL10 TNF
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
20 positive regulation of B cell proliferation GO:0030890 9.67 IL2 IL4 TNFRSF4
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 IFNG IL18 IL2 IL4
22 positive regulation of immunoglobulin secretion GO:0051024 9.66 IL2 TNFRSF4
23 interleukin-2-mediated signaling pathway GO:0038110 9.66 IL2 IL2RA
24 positive regulation of isotype switching to IgG isotypes GO:0048304 9.65 IL2 IL4
25 endothelial cell apoptotic process GO:0072577 9.64 IL10 TNF
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL10 IL4
27 positive regulation of activated T cell proliferation GO:0042104 9.63 IL18 IL2 IL2RA
28 necroptotic signaling pathway GO:0097527 9.62 FASLG TNF
29 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 IL10 TNF
30 negative regulation of lymphocyte proliferation GO:0050672 9.61 IL2 IL2RA
31 positive regulation of neuroinflammatory response GO:0150078 9.61 IL18 TNF
32 positive regulation of T cell differentiation GO:0045582 9.61 IL2 IL2RA IL4
33 positive regulation of tissue remodeling GO:0034105 9.6 IL18 IL2
34 regulation of regulatory T cell differentiation GO:0045589 9.58 IFNG IL2 IL2RA
35 regulation of isotype switching GO:0045191 9.57 IL10 IL4
36 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 IFNG TNF
37 receptor biosynthetic process GO:0032800 9.52 IL10 TNF
38 regulation of T cell homeostatic proliferation GO:0046013 9.51 IL2 IL2RA
39 positive regulation of interleukin-17 production GO:0032740 9.5 IL18 IL2 NOD2
40 cytokine-mediated signaling pathway GO:0019221 9.5 FASLG IL10 IL18 IL2 IL2RA IL4
41 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 IFNG TNF
42 type 2 immune response GO:0042092 9.43 IL10 IL18 IL4
43 immune response GO:0006955 9.28 FASLG IFNG IL10 IL18 IL2 IL2RA
44 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 IL10 IL18 IL2 IL4 NOD2 TNF

Molecular functions related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.77 ARHGAP45 FASLG GZMB IFNG IL10 IL18
2 cytokine activity GO:0005125 9.17 FASLG IFNG IL10 IL18 IL2 IL4

Sources for Acute Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....